The authors wish to retract this paper owing to the use of misidentified cell lines in the study. According to the description on the ATCC official website and reanalysis of the STR for cell line authentication, two misidentified glioblastoma cell lines, U251MG and U373MG, were used in this work. Based on recent literature (Torsvik et al. Cancer Med 2014; 3: 812-824), these two lines are thought to be cross-contaminated. Any data from misidentified or cross-contaminated cell lines are misleading-rendering conclusions incorrect.
